Aude Ambresin

Lausanne, VD, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 77 publications

Persistent placoid maculopathy: long term outcomes and prognostic factors.

Persistent placoid maculopathy: long term outcomes and prognostic factors.

Journal: Retina (Philadelphia, Pa.)

Published: June 26, 2026

Six-Month Real-World Data in Macular Edema Due to Retinal Vein Occlusion Treated with Faricimab: Swiss Retina Research Network Report.

Six-Month Real-World Data in Macular Edema Due to Retinal Vein Occlusion Treated with Faricimab: Swiss Retina Research Network Report.

Journal: Ophthalmology and therapy

Published: May 04, 2026

Practical Challenges for the Implementation of AI-Based Image Analysis in Ophthalmology Research: Insights and Recommendations from a Swiss Multicentric Study.

Practical Challenges for the Implementation of AI-Based Image Analysis in Ophthalmology Research: Insights and Recommendations from a Swiss Multicentric Study.

Journal: Klinische Monatsblatter fur Augenheilkunde

Published: April 20, 2026

Correction: One-Year Outcomes of Faricimab in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report.

Correction: One-Year Outcomes of Faricimab in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report.

Journal: Ophthalmology and therapy

Published: February 28, 2026

One-Year Real-World Outcomes of Switching to Aflibercept 8 mg in Eyes with Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report.

One-Year Real-World Outcomes of Switching to Aflibercept 8 mg in Eyes with Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report.

Journal: Ophthalmology and therapy

Published: January 06, 2026

Pigment epithelial detachment as a biomarker for faricimab treatment outcomes in naïve neovascular age-related macular degeneration.

Pigment epithelial detachment as a biomarker for faricimab treatment outcomes in naïve neovascular age-related macular degeneration.

Journal: European journal of ophthalmology

Published: December 17, 2025

Synergising Macular Function and Structure in Diabetic Macular Oedema to Improve Patient Care: An International Delphi Consensus.

Synergising Macular Function and Structure in Diabetic Macular Oedema to Improve Patient Care: An International Delphi Consensus.

Journal: Ophthalmology and therapy

Published: December 15, 2025

One-Year Real-World Outcomes of Aflibercept 8 mg in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report.

One-Year Real-World Outcomes of Aflibercept 8 mg in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report.

Journal: Ophthalmology and therapy

Published: December 01, 2025

Twelve-Month Outcomes Using Aflibercept 8 mg in Treatment-Naïve and Pretreated Diabetic Macular Edema: A Swiss Retina Research Network Report.

Twelve-Month Outcomes Using Aflibercept 8 mg in Treatment-Naïve and Pretreated Diabetic Macular Edema: A Swiss Retina Research Network Report.

Journal: Ophthalmology science

Published: November 08, 2025

Early Outcomes of Intravitreal Aflibercept 8 mg in Eyes Previously Treated with Aflibercept 2 mg for Neovascular Age-Related Macular Degeneration with AI-Based Biomarker Quantification.

Early Outcomes of Intravitreal Aflibercept 8 mg in Eyes Previously Treated with Aflibercept 2 mg for Neovascular Age-Related Macular Degeneration with AI-Based Biomarker Quantification.

Journal: Ophthalmology and therapy

Published: October 07, 2025

Establishing Expert Consensus on a Unified Decision Framework for Retina Patient Care.

Establishing Expert Consensus on a Unified Decision Framework for Retina Patient Care.

Journal: Ophthalmology and therapy

Published: September 01, 2025

Loading dose and 12-month outcomes in treatment-naïve patients with neovascular age-related macular degeneration treated with faricimab, with AI-based analysis of fluid dynamics.

Loading dose and 12-month outcomes in treatment-naïve patients with neovascular age-related macular degeneration treated with faricimab, with AI-based analysis of fluid dynamics.

Journal: International ophthalmology

Published: August 12, 2025

Showing 1-12 of 77

Last Updated: 09/26/2026